AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
HIV vaccine candidate taken by into phase I trial in U.S., Africa.
2003 MAY 7 - (NewsRx.com & NewsRx.net) -- Epimmune, Inc., (EPMN) announced that the National Institute of Allergy and Infectious Diseases, a component of the U.S. National Institutes of Health (NIH), holds an active Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA) to test Epimmune's multi-epitope vaccine, EP HIV-1090, to prevent HIV infection.
A multisite, phase I trial was recently initiated by the HIV Vaccine Trials Network (HVTN), which is conducting the trial. Trial sites include several New England and one African (Botswana) site associated with Harvard University, and one site associated with Saint Louis University. The total planned trial enrollment is 42 subjects, and the primary endpoint of the trial will be to determine the safety of the vaccine.
Mark Newman, PhD, VP of infectious diseases at Epimmune said, "We are very pleased to see our EP HIV-1090 vaccine, which Epimmune is evaluating under our own IND in a therapeutic setting in HIV-1-infected patients, also being evaluated in a prophylactic setting by the NIH. Because the HVTN has extensive experience in prophylactic ...
- International HIV vaccine trial under way in Africa and the United States.
- Newspaper article from: AIDS Weekly July 28, 2003 700+ words
...is being conducted through the HIV Vaccine Trials Network (HVTN) of the...immune response of an experimental HIV Vaccine called EP HIV-1090, known as a "DNA plasmid...this vaccine." While several HIV vaccine trials have been undertaken by...
- Patient enrollment completed in HIV vaccine trial.
- Newspaper article from: Virus Weekly February 17, 2004 700+ words
...phase I/II therapeutic HIV vaccine trial of its EP HIV-1090 vaccine candidate...system, primed with the EP HIV-1090 vaccine, can...million NIH HVDDT (HIV Vaccine Design and Development...vaccines." Epimmune's EP HIV-1090 vaccine candidate...
- Epimmune Completes Patient Enrollment in HIV Vaccine Trial; Vaccine Designed to...
- Press release article from: PR Newswire January 20, 2004 700+ words
...Phase I/II therapeutic HIV vaccine trial of its EP HIV-1090 vaccine candidate...system, primed with the EP HIV-1090 vaccine, can...million NIH HVDDT (HIV Vaccine Design and Development...vaccines." Epimmune's EP HIV-1090 vaccine candidate...
- Preliminary EP HIV-1090 trial data presented at international AIDS conference.
- Newspaper article from: Biotech Week August 11, 2004 700+ words
...ongoing phase I trials of its EP HIV-1090 therapeutic vaccine...which is a multiepitope HIV vaccine candidate. In this trial...U.S. and Africa by the HIV Vaccine Trials Network (HVTN...and commercialization of an HIV vaccine using our technology. EP1090...
- HIV vaccine candidate taken by into phase I trial in U.S., Africa.
- Newspaper article from: Virus Weekly May 6, 2003 700+ words
...epitope vaccine, EP HIV-1090, to prevent...initiated by the HIV Vaccine Trials Network...pleased to see our EP HIV-1090 vaccine...to evaluate our HIV vaccine candidate...progress toward an HIV vaccine and controlling...inventors." The EP ...
- Epimmune's HIV Vaccine Candidate Taken by the National Institutes of Health and...
- Press release article from: PR Newswire April 7, 2003 700+ words
...epitope vaccine, EP HIV-1090, to prevent...initiated by the HIV Vaccine Trials Network...pleased to see our EP HIV-1090 vaccine...to evaluate our HIV vaccine candidate...progress toward an HIV vaccine and controlling...inventors." The EP ...
- NIH unit takes up Epimmune's HIV vaccine candidate.
- Newspaper article from: Pharma Marketletter April 14, 2003 700+ words
...Drug Administration to test the firm's multi-epitope vaccine, EP HIV-1090, to prevent HIV infection. A multi-site, Phase I trial was recently initiated by the HIV Vaccine Trials Network, which is conducting the study. Trial locations...
- $16.7M NIH contract to develop HIV vaccine.
- Newspaper article from: Biotech Week October 29, 2003 700+ words
...evaluation by the NIAID-sponsored HIV Vaccine Trials Network (HVTN). The award was made under the NIAID's HIV Vaccine Design and Development Teams (HVDDT...trials are being conducted with our EP HIV-1090 DNA vaccine candidate." This...